KMT2D and cancer: The BRAF oncogene was found to be mutated in 8% of cancers, which is only marginally less common than KRAS. Three epigenetic modifiers (KMT2C, KMT2D, and ARID1A) were among the ten most frequently mutated cancer driver genes, highlighting the frequency of epigenetic dysregulation in cancer43.